Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Features and Treatment of Systemic JIA in Children
Sponsor: Sohag University
Summary
This study aims to describe the clinical features, disease patterns, and different treatment modalities used in children with systemic juvenile idiopathic arthritis (sJIA). The study will include children younger than 18 years who meet the established classification criteria for sJIA. Clinical findings, laboratory investigations, disease activity, complications, and treatments received will be assessed. Participants will be followed prospectively to evaluate their clinical course and response to different therapeutic approaches. The study will help improve understanding of sJIA in children and provide information about the outcomes associated with different treatment modalities.
Official title: Clinical Characterization and Different Therapeutic Modalities in Children With Systemic Juvenile Idiopathic Arthritis
Key Details
Gender
All
Age Range
Any - 18 Years
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2026-10-01
Completion Date
2027-09-01
Last Updated
2026-09-11
Healthy Volunteers
No
Interventions
Tocilizumab (Actemra®)
Tocilizumab used as part of routine clinical care for the management of systemic juvenile idiopathic arthritis. The treatment regimen, duration, and clinical response will be documented according to the treating physician's clinical practice.
Locations (1)
Sohag university hospital
Sohag, Egypt